Open house discount agreements for Botulinumtoxin Typ A Xeomin
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Botulinumtoxin Typ A, Fertigarzneimittelbezeichnung Xeomin(R), ATC M03AX21
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No information on volumes or expected discounts; revenue potential is unknown.
Manual paper submission requires two original copies; electronic submission requires qualified electronic signature.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Feb 2027
- Non-exclusive discount agreements for Botulinumtoxin Typ A (Xeomin) under §130a Abs. 8 SGB V.
- Contractors are pharmaceutical companies that meet eligibility criteria.
Show full summary
This is an open-house model for non-exclusive discount agreements on Botulinumtoxin Typ A (Xeomin) with AOK Bayern in Germany. It is not a traditional procurement; any eligible pharmaceutical company can join. The contract runs from March 1, 2025 to February 28, 2027, with possible termination. No estimated value is provided. Only one lot exists. Eligibility is proven via a signed self-declaration of reliability. Submission can be in paper or electronic form with qualified signature. Documents are available on dtvp.de.
Risks
No information on volumes or expected discounts; revenue potential is unknown.
Manual paper submission requires two original copies; electronic submission requires qualified electronic signature.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Only pharmaceutical companies can participate.
Certifications
- Documents must be in German or accompanied by a certified German translation.
Administrative
- Must submit a signed self-declaration of reliability.
Requirements may be incomplete.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house discount agreements for Botulinumtoxin Typ A Xeomin
Non-exclusive discount agreements for the active ingredient Botulinumtoxin Typ A, finished medicinal product Xeomin (R), ATC M03AX21. Contractors can join anytime until January 5, 2027. The agreement ends February 28, 2027.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Botulinumtoxin Typ A, Fertigarzneimittelbezeichnung Xeomin(R), ATC M03AX21
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 16 Jan 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 34179-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No information on volumes or expected discounts; revenue potential is unknown.
Manual paper submission requires two original copies; electronic submission requires qualified electronic signature.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications